Calbindin-D28K acts as a calcium-dependent chaperone suppressing α-synuclein fibrillation in vitro

Abstractα-Synuclein, a natively unfolded protein aggregation which is implicated in the pathogenesis of Parkinson’s disease and several other neurodegenerative diseases, is known to interact with a great number of unrelated proteins. Some of these proteins, such as β-synuclein and DJ-1, were shown to inhibit α-synuclein aggregation in vitro and in vivo therefore acting as chaperones. Since calbindin-D28K is co-localized with Ca2+ neuronal membrane pumps, and since α-synuclein is also found in the membrane proximity, these two proteins can potentially interact in vivo. Here we show that calbindin-D28K interacts with α-synuclein and inhibits its fibrillation in a calcium-dependent manner, therefore potentially acting as a calcium-dependent chaperone.

[1]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[2]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[3]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[4]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .

[5]  A. Abeliovich,et al.  DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.

[6]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[7]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[8]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[9]  H. Erdjument-Bromage,et al.  Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. , 2003, The Journal of biological chemistry.

[10]  Vladimir N Uversky,et al.  A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.

[11]  A. Norman,et al.  Ontogeny of the calcium binding protein calbindin D-28k in the rat nervous system , 2004, Anatomy and Embryology.

[12]  V. Uversky,et al.  Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.

[13]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[14]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[15]  B. Hyman,et al.  Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. , 2001, Journal of neurochemistry.

[16]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[17]  Vladislav Yu Orekhov,et al.  Binding of intrinsically disordered proteins is not necessarily accompanied by a structural transition to a folded form. , 2007, Biochimie.

[18]  V. Uversky,et al.  Natively unfolded C‐terminal domain of caldesmon remains substantially unstructured after the effective binding to calmodulin , 2003, Proteins.

[19]  V. Uversky,et al.  Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.

[20]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[21]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[23]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[24]  P. Mcgeer,et al.  Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K , 1990, Brain Research.

[25]  R. Nussbaum,et al.  Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.

[26]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[27]  Min Zhu,et al.  Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.

[28]  P. Gaspar,et al.  Sparing of the dopaminergic neurons containing Calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice , 1994, Neuroscience.

[29]  A. Parent,et al.  Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. , 1991, Neuroreport.

[30]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.

[31]  Vladimir N Uversky,et al.  Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. , 2007, Journal of neurochemistry.

[32]  Mark A. Wilson,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .

[33]  B. Hyman,et al.  Characterization of the Precursor Protein of the Non-Aβ Component of Senile Plaques (NACP) in the Human Central Nervous System , 1996, Journal of neuropathology and experimental neurology.

[34]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[36]  A. Sigalov,et al.  The intrinsically disordered cytoplasmic domain of the T cell receptor zeta chain binds to the nef protein of simian immunodeficiency virus without a disorder-to-order transition. , 2008, Biochemistry.

[37]  S. Christakos,et al.  Vitamin D-dependent calcium binding proteins: chemistry, distribution, functional considerations, and molecular biology. , 1989, Endocrine reviews.

[38]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[39]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[40]  A. Sigalov.  Signaling chain homooligomerization (SCHOOL) model. , 2008, Advances in experimental medicine and biology.

[41]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[42]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[43]  Min Zhu,et al.  Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.

[44]  V. Buchman,et al.  Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. , 2003, Neuropharmacology.

[45]  M. Gross,et al.  Physiology and biochemistry of vitamin D-dependent calcium binding proteins. , 1990, The American journal of physiology.

[46]  M. Celio,et al.  Calbindin D-28k and parvalbumin in the rat nervous system , 1990, Neuroscience.

[47]  H. Erdjument-Bromage,et al.  Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate* , 2003, The Journal of Biological Chemistry.

[48]  Jing Zhang,et al.  Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1*S , 2007, Molecular & Cellular Proteomics.

[49]  Ralf Langen,et al.  Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  B. A. Brooks,et al.  Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a , 1992, Annals of the New York Academy of Sciences.

[51]  G. Petsko,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.

[52]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[53]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[54]  Reinhard Jahn,et al.  A Broken α-Helix in Folded α-Synuclein* , 2003, The Journal of Biological Chemistry.

[55]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[56]  P. P. Lele,et al.  Sensory nerves of the cornea and cutaneous sensibility. , 1959, Experimental neurology.

[57]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[58]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[59]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[60]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[61]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[62]  R. Gainetdinov,et al.  Experimental Genetic Approaches to Addiction , 2002, Neuron.

[63]  J. T. Penniston,et al.  Immunocytochemical localization of the plasma membrane calcium pump, calbindin-D28k, and parvalbumin in Purkinje cells of avian and mammalian cerebellum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Scarlata,et al.  Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.

[65]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[66]  P. Worley,et al.  Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. , 1999, Nature genetics.

[67]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[68]  C. Ballard,et al.  Neuroleptic drugs in dementia: benefits and harm , 2006, Nature Reviews Neuroscience.

[69]  T. Craig,et al.  Changes in structure and stability of calbindin-D(28K) upon calcium binding. , 2004, Analytical biochemistry.

[70]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[71]  B. Hyman,et al.  Interaction of α‐synuclein and synphilin‐1: effect of Parkinson's disease‐associated mutations , 2001 .